5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 11, 2015, Pages

  García Perdomo, Herney A ^a   Lopez, Hugo E ^b   Tacklind, James ^c  

^a UNIVERSIDAD DEL VALLE   (Colombia)

^b UNIVERSIDAD DEL ROSARIO   (Colombia)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ARTICLE; BENIGN PROSTATIC OBSTRUCTION; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE DISEASE; QUALITY OF LIFE; SYSTEMATIC REVIEW; URINE RETENTION; UROGENITAL TRACT DISEASE ASSESSMENT;

EID: 85041748285     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011928     Document Type: Article

References (27)

1. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. New England Journal of Medicine 2010;362(13):1192-202.
2. Barry MJ, Fowler FJ Jr, Bin L, Pits JC 3rd, Harris CJ, Mulley AG Jr. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. Journal of Urology 1997;157(1):10-4.
3. Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. British Medical Journal (Clinical Research Ed.) 2001;323(7320):1042-6. Erratum in: British Medical Journal (Clinical Research Ed.) 2002;324(7340):775.
4. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
5. Garraway WM, Russell EB, Lee RJ, Collins GN, McKelvie GB, Hehir M, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. British Journal of General Practice 1993;43(373):318-21.
6. Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE, et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994;44(6):825-31.
7. McMaster University (developed by Evidence Prime, Inc.). GRADEproGDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. Hamilton: McMaster University (developed by Evidence Prime, Inc.), 2015.
8. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Schünemann HJ, et al. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.) 2008;336(7651):995-8. [DOI: 10.1136/bmj.39490.551019.BE]
9. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [DOI: 10.1016/j.jclinepi.2010.04.026]
10. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
11. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
12. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
13. Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. American Journal of Managed Care 2006;12(4 Suppl):S83-9.
14. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. Journal of Urology 1996;155(2):595-600.
15. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. Journal of Urology 1997;158(2):481-7.
16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]
17. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donell RF, et al. American Urological Association guideline: management of benign prostatic hyperplasia (BPH). www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm (accessed 1 April 2015).
18. National Institute for Health and Care Excellence. Lower urinary tract symptoms in men: management. NICE guidelines [CG97]. www.nice.org.uk/guidance/cg97 (accessed 27 October 2015).
19. Pagano E, Laudato M, Griffo M, Capasso R. Phytotherapy of benign prostatic hyperplasia. A minireview. Phytotherapy Research: PTR 2014;28(7):949-55.
20. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
21. Roehrborn CG, Nuckolls JG, Wei JT, Steers W, BPH Registry and Patient Survey Steering Committee. The Benign Prostatic Hyperplasia Registry and Patient Survey: study design, methods and patient baseline characteristics. BJU International 2007;100(4):813-9.
22. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. European Urology 2010;57(1):123-31.
23. Rosen R, Altwein J, Boyle P, Kirby RS, Luckas B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). European Urolology 2003;44(6):637-49.
24. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
25. StataCorp . Stata Statistical Software: Release 13. College Station, TX: StataCorp LP, 2013.
26. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD001044]
27. Tacklind J, Fink HA, MacDonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2010, Issue 10. [DOI: 10.1002/14651858.CD006015.pub3]